RGNX REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1590877 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.6%
TTM net income YoY1.5%
TTM EPS YoY7.5%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-95.7%
Net margin-113.9%
FCF margin-100.6%
EBITDA margin-85.9%
Returns
ROE-113.2%
ROA-35.4%
ROIC (approx.)-150.2%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets68.2%
Debt / equity0.00x
Current ratio4.74x
Interest coverage-4.06x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.16M | $108.02M | $6.39M | $30.34M | $29.73M | $21.36M | $89.01M | $21.21M |
| Cost of revenue | — | — | — | — | — | — | — | $6.32M |
| Gross profit | — | — | — | — | — | — | — | $14.90M |
| R&D expense | $61.01M | $56.09M | $57.34M | $59.61M | $56.10M | $59.50M | $53.09M | $50.38M |
| SG&A expense | $20.58M | $21.62M | $21.31M | $22.38M | $20.25M | $19.88M | $20.35M | $20.05M |
| Operating income | -$35.53M | $29.26M | -$83.36M | -$57.64M | -$52.41M | -$63.28M | $12.13M | -$51.37M |
| Interest expense | $7.47M | $7.79M | $8.71M | $12.28M | $13.17M | $10.99M | $8.57M | $9.42M |
| Net income | -$40.74M | $22.71M | -$90.05M | -$67.15M | -$61.94M | -$70.87M | $6.08M | -$51.19M |
| EBITDA | -$32.02M | $33.02M | -$79.50M | -$53.77M | -$48.52M | -$59.37M | $16.08M | -$47.34M |
| EPS (basic) | -0.62 | 0.43 | -1.72 | — | -1.20 | -1.38 | 0.12 | — |
| EPS (diluted) | -0.62 | 0.43 | -1.72 | — | -1.20 | -1.38 | 0.12 | — |
| Weighted avg. shares (diluted) | 65.26M | 53.02M | 52.43M | — | 51.69M | 51.48M | 51.43M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $95.80M | $36.49M | $15.23M | $34.47M | $58.80M | $79.56M | $130.10M | $57.53M |
| Short-term investments | $155.18M | $69.03M | $135.26M | $195.60M | $215.40M | $243.74M | $137.76M | $177.16M |
| Receivables | $8.54M | $106.75M | $10.04M | $26.38M | $25.35M | $20.20M | $18.19M | $20.47M |
| Current assets | $320.89M | $236.16M | $186.52M | $281.28M | $331.97M | $373.75M | $313.24M | $278.00M |
| PP&E, net | $95.35M | $98.45M | $101.87M | $104.86M | $107.52M | $111.02M | $114.50M | $117.59M |
| Total assets | $466.04M | $386.62M | $341.89M | $453.03M | $525.20M | $581.03M | $490.93M | $465.99M |
| Current liabilities | $67.68M | $82.62M | $71.11M | $118.09M | $124.57M | $119.54M | $106.73M | $103.19M |
| Total liabilities | $318.00M | $314.85M | $320.81M | $350.30M | $363.75M | $367.35M | $216.73M | $206.34M |
| Shareholders' equity | $148.04M | $71.77M | $21.08M | $102.73M | $161.45M | $213.68M | $274.20M | $259.65M |
| Shares outstanding | 66.12M | 54.16M | 51.62M | 50.89M | 50.62M | 50.39M | 50.12M | 49.55M |
| Cash flow statement | ||||||||
| Operating cash flow | $38.61M | -$62.24M | -$76.19M | -$52.29M | -$55.96M | -$49.34M | $33.63M | -$31.62M |
| Capital expenditure | $194,000 | $760,000 | $1.24M | $508,000 | $491,000 | $391,000 | $1.02M | $1.08M |
| Free cash flow | $38.41M | -$63.00M | -$77.42M | -$52.80M | -$56.45M | -$49.73M | $32.60M | -$32.70M |
| Investing cash flow | -$86.15M | $65.92M | $70.59M | $37.54M | $42.29M | -$140.44M | $44.74M | $40.27M |
| Financing cash flow | $106.85M | $17.57M | -$13.64M | -$9.58M | -$7.08M | $139.23M | -$5.79M | -$7.74M |
| Depreciation & amortization | $3.52M | $3.76M | $3.86M | $3.87M | $3.89M | $3.90M | $3.96M | $4.02M |
| Stock-based compensation | $8.12M | $9.05M | $8.62M | $8.38M | $9.00M | $8.65M | $8.54M | $9.54M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.